EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis

Oliver J McElvaney, Sonya L Heltshe, Katherine Odem-Davis, Natalie E West, Don B Sanders, Barbra Fogarty, Donald R VanDevanter, Patrick A Flume, Christopher H Goss

Annals of the American Thoracic Society · 2024

DOI: 10.1513/annalsats.202308-673oc ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of the American Thoracic Society, 2024. Verfasst von Oliver J McElvaney und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, Washington. Hauptthemen laut MEDLINE: Cystic Fibrosis, Adrenal Cortex Hormones, Disease Progression. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Pulmonary exacerbations (PEx) remain the most common cause of morbidity, recurrent hospitalization, and diminished survival in people with cystic fibrosis (PWCF) and are characterized by excess inflammation. Corticosteroids are potent, widely available antiinflammatory drugs. However, corticosteroid efficacy data from randomized controlled trials in PWCF are limited.

Objectives

To determine whether adjunctive systemic corticosteroid therapy is associated with improved outcomes in acute CF PEx.

Methods

We performed a secondary analysis of Standardized Treatment of Pulmonary Exacerbations 2 (STOP2), a large multicenter randomized controlled trial of antimicrobial treatment durations for adult PWCF presenting with PEx, that included the use of corticosteroids as a stratification criterion in its randomization protocol. Corticosteroid treatment effects were determined after propensity score matching for covariates including age, sex, baseline forced expiratory volume in 1 second (FEV1), genotype, and randomization arm. The primary outcome measure was the change in percentage predicted FEV1 (ppFEV1). Symptoms, time to next PEx, and the incidence of adverse events (AEs) and serious adverse events (SAEs) were assessed as secondary endpoints. Phenotypic factors associated with the clinical decision to prescribe steroids were also investigated.

Results

Corticosteroids were prescribed for 168 of 982 PEx events in STOP2 (17%). Steroid prescription was associated with decreased baseline ppFEV1, increased age, and female sex. Cotreatment with corticosteroids was independent of treatment arm allocation and did not result in greater mean ppFEV1 response, longer median time to next PEx, or more substantial symptomatic improvement compared with propensity-matched PWCF receiving antibiotics alone. AEs were not increased in corticosteroid-treated PWCF. The total number of SAEs—but not the number of corticosteroid-related or PEx-related SAEs—was higher among patients receiving corticosteroids.

Conclusions

Empiric, physician-directed treatment with systemic corticosteroids, although common, is not associated with improved clinical outcomes in PWCF receiving antibiotics for PEx. Clinical trial registered with www.clinicaltrials.gov (NCT02781610).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAdrenal Cortex HormonesDisease ProgressionHumansFemaleMaleAdultForced Expiratory VolumeYoung AdultPropensity ScoreAnti-Bacterial AgentsTreatment OutcomeDrug Therapy, CombinationAdolescent

Stichwörter der Autor:innen

CFPExclinical trialcorticosteroidsrespiratory infection

Substanzen

Adrenal Cortex HormonesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, Washington.
  • Department of Medicine and.
  • Department of Pediatrics, University of Washington, Seattle, Washington.
  • Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Department of Pediatrics, Indiana University, Indianapolis, Indiana.
  • Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio; and.

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • Cystic Fibrosis Foundation
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Zitieren

APA

McElvaney, O. J., Heltshe, S. L., Odem-Davis, K., West, N. E., Sanders, D. B., Fogarty, B., VanDevanter, D. R., Flume, P. A., & Goss, C. H. (2024). Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis. Annals of the American Thoracic Society. https://doi.org/10.1513/annalsats.202308-673oc

Vancouver

McElvaney OJ, Heltshe SL, Odem-Davis K, West NE, Sanders DB, Fogarty B, et al. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis. Annals of the American Thoracic Society. 2024. doi:10.1513/annalsats.202308-673oc

BibTeX
@article{McElvaney2024,
  author = {McElvaney, Oliver J and Heltshe, Sonya L and Odem-Davis, Katherine and West, Natalie E and Sanders, Don B and Fogarty, Barbra and VanDevanter, Donald R and Flume, Patrick A and Goss, Christopher H},
  title = {Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis},
  journal = {Annals of the American Thoracic Society},
  year = {2024},
  doi = {10.1513/annalsats.202308-673oc}
}
Kostenlos starten →